Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

AdcendoAnnounceChange

More Like This

PR Newswire associated0

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline

PR Newswire associated0

Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

PR Newswire associated0

Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

PR Newswire associated0

Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02

PR Newswire associated0

Prescient Healthcare Group Announces the Appointment of Two New Members to Its Board of Directors

Merck invests €70 million to triple its antibody-drug conjugate (ADC) manufacturing capacity and upgrade 3200 m2 at its BioConjugation Center of Excellence in St. Louis, Missouri, USA. (Photo: Business Wire)

Merck Invests €70 Million to Expand ADC Manufacturing for Novel Cancer Therapies

Avance Clinical Announces Senior Appointment to North American Operations